Pinnbrook Capital Management LP Makes New $1.50 Million Investment in Revvity Inc. $RVTY

Pinnbrook Capital Management LP purchased a new position in Revvity Inc. (NYSE:RVTY) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 13,500 shares of the company’s stock, valued at approximately $1,502,000.

Several other institutional investors and hedge funds have also made changes to their positions in RVTY. BlackRock Inc. purchased a new stake in Revvity during the 2nd quarter worth about $852,070,000. Norges Bank acquired a new position in Revvity in the 4th quarter valued at about $80,382,000. Bank of New York Mellon Corp purchased a new position in Revvity in the 2nd quarter valued at about $78,766,000. Morgan Stanley lifted its holdings in Revvity by 29.6% in the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after purchasing an additional 650,083 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Revvity by 7.0% during the 4th quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock worth $789,595,000 after purchasing an additional 533,912 shares during the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Stock Up 0.6%

Shares of NYSE:RVTY opened at $124.88 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The firm has a market cap of $13.94 billion, a price-to-earnings ratio of 59.47, a PEG ratio of 2.27 and a beta of 1.07. The stock’s 50-day moving average price is $111.45 and its two-hundred day moving average price is $100.37. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $124.97.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same quarter in the prior year, the company posted $1.18 EPS. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Sanford C. Bernstein initiated coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price objective on the stock. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Barclays lifted their target price on shares of Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Finally, Zacks Research upgraded Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.